Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
CRO
FDA draft recommends all cancer trials collect OS data
Even when OS is not used as the primary endpoint, the FDA still advises that trial sponsors collect and submit survival data to the regulator.
Darren Incorvaia
Aug 20, 2025 10:59am
Genentech scraps $2B cell therapy pact with Adaptive
Aug 18, 2025 2:40pm
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
Gilead culls last MASH program, 2 cancer assets
Aug 8, 2025 11:50am
Radiopharma biotech Artbio paints path to clinic with $132M
Jul 29, 2025 7:30am
Processa hands cancer drug back to Opus over time, cost involved
Jul 1, 2025 11:12am
